On Jul. 15, 2020, Tevogen Bio announced its intention to evaluate its proprietary antigen-specific T cell technology as a potential treatment for COVID-19 patients.

In addition, Tevogen also announced developing of a bivalent COVID-19 and Influenza vaccine to assess its ability to generate cellular immunity.

Tevogen Bio was formed after decades of research by its contributors to concentrate and leverage their expertise, spanning multiple sectors of the health care industry, to help address some of the most common and deadly illnesses known today.